Startsida500124 • BOM
add
Dr Reddy's Laboratories Ltd
Föregående stängning
1 194,55 ₹
Dygnsintervall
1 194,00 ₹ - 1 222,85 ₹
Årsintervall
1 074,35 ₹ - 1 420,20 ₹
Börsvärde
1,01 bn INR
Genomsnittlig volym
59,31 tn
P/E-tal
18,98
Direktavkastning
0,66 %
Primär börs
NSE
Ekonominyheter
Ekonomi
Resultaträkning
Intäkter
Nettoinkomst
(INR) | sep. 2024info | Förändring Y/Y |
---|---|---|
Intäkter | 80,16 md | 16,51 % |
Rörliga kostnader | 29,72 md | 24,54 % |
Nettoinkomst | 12,55 md | −15,18 % |
Nettovinstmarginal | 15,66 | −27,20 % |
Vinst per aktie | 15,83 | −11,13 % |
EBITDA | 22,02 md | 8,53 % |
Giltig skattesats | 30,01 % | — |
Balansräkning
Totala tillgångar
Totala ansvarsskyldigheter
(INR) | sep. 2024info | Förändring Y/Y |
---|---|---|
Kontanta och kortsiktiga investeringar | 63,07 md | −7,15 % |
Totala tillgångar | 465,96 md | 34,27 % |
Totala ansvarsskyldigheter | 156,67 md | 66,79 % |
Totala tillgångar | 309,28 md | — |
Utestående aktier | 833,05 mn | — |
P/B | 3,26 | — |
Avkastning på tillgångar | 10,24 % | — |
Avkastning på kapital | 13,21 % | — |
Kassaflöde
Förändring i nettokassa
(INR) | sep. 2024info | Förändring Y/Y |
---|---|---|
Nettoinkomst | 12,55 md | −15,18 % |
Kontanter från verksamhet | 9,32 md | −48,03 % |
Kontanter från investering | −19,07 md | −322,21 % |
Kontanter från finansiering | 16,15 md | 329,53 % |
Förändring i nettokassa | 6,37 md | 1,03 % |
Fritt kassaflöde | 3,92 md | −72,47 % |
Om
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Grundades
1984
Huvudkontor
Hemsida
Anställda
27 048